Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 116 posts
CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
May 7, 2020 | Podcasts

CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?

Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 5, 2020 | Podcasts

Speaking of Access: Pricing for Uncertain Indications

Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.

April 30, 2020 | Culture Blog, News

cbpGIVES Raises $4,150 Within the Firm to Support COVID-19 Relief Efforts

The global COVID-19 crisis has affected many individuals worldwide in substantial ways, including increasing food insecurity, medical burden and economic loss. CBPartners' charitable faction cbpGIVES coordinated efforts firm-wide to raise funds to support COVID-19 relief. CBPartners has matched every dollar raised by employees and have raised a total of $4,150 to donate to several organizations across the world.

covid trial disruptions
April 29, 2020 | Blog

Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.

CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
April 21, 2020 | Podcasts

CBPartners’ Pharma Take-Away: COVID-19 (Pt 2): Promising Treatments in Development

In Part 2 of the COVID-19 series, healthcare consultant Jared Wolff is again joined by Matthew Rube and Akhil Parlapalli from CBPartners’ New York office to discuss some of the most promising treatments that are currently being put to the test against COVID-19.